Top list of global pharmaceutical companies by market value!

A few days ago, the Visual Capital website sorted out the global market value ranking of pharmaceutical companies, and listed the market value of pharmaceutical companies in North America, Europe and Asia

The top ten global pharmaceutical companies by market value (Source: Visual Capital Network, statistics as of June 23)

North America:

Johnson & Johnson's market value exceeds 400 billion U.

It is worth noting that some pharmaceutical giants have played a central role in the fight against the new crown epidemic and are expected to substantially increase their income, including Pfizer and Moderna

Leading pharmaceutical company in North America by market value

  Not long ago, according to the Wall Street Journal, Alex Gorsky, who has been CEO of Johnson & Johnson for nearly 10 years, announced that he will step down.
His long-term deputy, Joaquin Duato, will take over on January 3, 2022 and become the new CEO of the world’s largest healthcare company
.
During Gorsky’s tenure, Johnson & Johnson has achieved tremendous growth.
Its market value has grown from nearly US$180 billion to more than US$470 billion.
The stock price has risen by more than 170%.
At the same time, it has problems with the production of consumer health business, opioids and talc products.
Relevant litigation issues were dealt with, and he led the acquisition of Actelion for US$30 billion to expand the rare disease pipeline, which is also Johnson & Johnson’s largest transaction to date
.
  

  In the first half of this year, Johnson & Johnson achieved growth in its pharmaceutical, medical device, and consumer healthcare businesses
.
The strengths of Johnson & Johnson's pharmaceutical business segment are tumors and autoimmune diseases.
Product growth is mainly driven by several products such as Stelara, Darzalex, Imbruvica, Tremfya, and Erleada
.
In addition, the new crown vaccine has contributed a good growth force, achieving revenue of 264 million US dollars
.
Johnson & Johnson expects its global new crown vaccine sales this year to reach 2.
5 billion US dollars
.
At the same time, Johnson & Johnson expects sales in 2021 to be between 90.
5 billion and 91.
7 billion U.
S.
dollars.
Based on the current momentum, Johnson & Johnson’s sales are expected to exceed 90 billion U.
S.
dollars in 2021
.

  2  Pfizer

  As the global epidemic continues, the new crown pneumonia vaccine has become the best-selling medical product
.
The new crown vaccine BNT162b2 jointly developed by Pfizer and BioNTech is expected to have revenue of approximately US$33.
5 billion in 2021.
BNT162b2 will also surpass "the king of medicine" Humira and become the drug with the highest sales in history
.
To this end, Pfizer raised its expected full-year revenue for 2021 to US$78 billion to US$80 billion, which is expected to nearly double Pfizer’s total revenue in 2020 (US$41.
9 billion)
.
  

  Although Pfizer is the leading manufacturer of new crown vaccines in North America, it has slipped to third place in the global market value ranking
.
A few days ago, an FDA expert advisory panel voted 16 to 2 to reject the plan to inject Pfizer's new crown vaccine booster for people 16 years and older
.
According to the recommendations of the members of the group, the elderly and vulnerable groups may benefit from enhanced needles, but there is insufficient data on whether enhanced needles are effective for younger groups
.
Statistics show that Pfizer has lost $37 billion in market value in the past month
.

  3  Eli Lilly

  Eli Lilly's market capitalization ranking is advancing rapidly
.
The market value in 2019 was US$125 billion, and it has now exceeded US$200 billion, achieving significant growth
.
Especially in 2020, Eli Lilly’s stock market has performed outstandingly and is one of the pharmaceutical companies with the largest market capitalization increase, increasing by 28%
.
In the first half of this year, the market value of Eli Lilly continued to rise sharply, mainly due to the new Alzheimer's disease antibody drug Donanemab, and tirzepatide phase 3 head-to-head clinical defeat of Novo Nordisk Meglutide
.
   

Europe:

Roche leads Bayer in deep trouble

  The European pharmaceutical company with the highest market value is Roche, ranking second in the world, with a market value of US$320 billion
.
Novartis, Novo Nordisk, and AstraZeneca are also among the top 10 pharmaceutical companies in the world by market capitalization
.
It is worth noting that Bayer, which ranked second in the “Top 10 Global Most Valuable Pharmaceutical Brands in 2019” released by Brand Finance, had a market value of US$80 billion in 2016 and spent US$66 billion to acquire Monsanto.
After a series of turmoil, the stock price did not rise but fell.
Now Bayer's market value is only more than 50 billion US dollars
.
Affected by the provision of special expenses (3.
9 billion euros) related to the glyphosate litigation, Bayer had a net loss of 2.
33 billion euros in the second quarter
.
In 2020, Bayer has provided more than 10 billion euros in reserves for glyphosate litigation
.

  Leading pharmaceutical company in Europe by market capitalization

  Roche is at the forefront of oncology, immunology, infectious diseases, ophthalmology and neuroscience
.
In the first half of the year, Roche topped the list of R&D investment with US$6.
917 billion, and R&D expenses accounted for 33% of revenue
.
In the expansion of core products, multiple sclerosis, hemophilia, and tumors are the focus.
Multiple sclerosis drug Ocrevus, breast cancer drug Perjrta, PD-L1 drug Tecentriq, and hemophilia drug Hemlibra performed well
.
  

  In the first half of the year, Roche launched 12 new phase III clinical trials, and 5 key clinical data will be released in the second half of 2021, including CD3/CD20 dual anti-mosunetuzumab for third-line and later follicular lymphoma, CD3/CD20 dual Anti-glofitamab is used for third-line and later diffuse large B-cell lymphoma, etc.
, and the number of pipelines in the clinical and subsequent stages is up to 150
.

  2  Novartis

  As the second largest pharmaceutical company in Switzerland, Novartis has ranked first in the number of drugs under research in the world for five consecutive years
.
Compared with other pharmaceutical companies, Novartis has the advantage that its self-developed products account for a higher proportion
.
According to statistics, in 2021, Novartis has 145 self-developed drugs, accounting for 62.
5% of the total
.
In addition, Novartis is in a leading position in four fields: vaccines, healthcare products, biopharmaceuticals, and generic drugs.
At present, it has 66 public pipelines under research.
Product development includes oncology, ophthalmology, respiratory system, cardiovascular and generic drugs, etc.
Multiple areas
.
  

  The main products driving performance growth include Cosentyx, Entresto, Zolgensma and Kesimpta
.
At the same time, new drugs have achieved positive results in the field of diseases with unmet needs, including iptacopan for the treatment of a series of immune-mediated diseases, and 177Lu-PSMA-617 for the treatment of prostate cancer
.

Asia:

Hengrui accelerates "going out to sea" Takeda model becomes a model

  According to relevant data from Ai Kunwei, it is estimated that from 2021 to 2025, global medical expenditures (calculated by fares) will increase at an average annual rate of 3% to 6%, and will reach US$1.
6 trillion by 2025
.
Among them, the strong development of emerging pharmaceutical markets will become the main force in the growth of global pharmaceutical expenditures; the growth of pharmaceutical expenditures in developed countries and regional markets will slow down
.
Among them, China's drug expenditure has increased from 56 billion U.
S.
dollars in 2010 to 134 billion U.
S.
dollars in 2020
.
It is expected that in the next five years, as China continues to update the national medical insurance drug catalog, more original research drugs will be included in the medical insurance, and the level of drug expenditure will continue to increase
.
It is estimated that by 2025, China's drug expenditure will exceed 170 billion U.
S.
dollars
.
  

  Specific to the Asian region, Hengrui Pharmaceuticals, Takeda, Celltrion, Astellas, and BeiGene are among the top in terms of value.
Hengrui Pharmaceuticals once topped Asia's most valuable pharmaceutical company, but has fallen below Takeda after the stock price correction
.
With Chinese pharmaceutical companies getting closer to the international market, Hengrui Pharmaceuticals and BeiGene are already at the top level in Asia
.
In addition, Visual Capital’s statistics include Lonza.
WuXi AppTec and WuXi Biologics, both of which are CDMOs, have surpassed Lonza and are already the world’s leading CDMO in terms of market value
.

  Top pharmaceutical companies in Asia by market capitalization

  Hengrui once announced at the end of 2019 to cut 70% of generic drugs and accelerate the transformation to innovative drugs
.
Today, Hengrui is facing common problems encountered by companies transforming from generic drugs to innovative drugs.
Generic drugs are falling off a cliff, and innovative drugs are gradually increasing
.
With Sun Piaoyang taking the helm for the second time, Hengrui continues to adhere to the strategy of innovation and internationalization
.
At present, Hengrui Medicine has launched 8 innovative drugs including carrelizumab, errecoxib, and apatinib mesylate in China, and more than 50 innovative drugs are under clinical development and more than 240 clinical drugs Tests are carried out at home and abroad
.
In the first half of the year, Hengrui Pharmaceuticals invested a total of 2.
581 billion yuan in research and development funds, a year-on-year increase of 38.
48%, accounting for 19.
41% of sales revenue, ranking the forefront of the national pharmaceutical industry
.
  

  At the same time, Hengrui Medicine has established R&D centers or branches in many places in China, the United States, Europe, Japan and other places, and has an innovative drug R&D team of more than 4,500 people
.
Hengrui is also accelerating its "going abroad".
In April of this year, karelizumab for hepatocellular carcinoma indications was granted orphan drug designation by the US FDA, and the fastest-growing karelizumab combined with apa The tinib combination is expected to become Hengrui's first new molecular product to be marketed overseas
.

  2  Takeda

  As the largest pharmaceutical company in Japan, Takeda focuses on drug R&D in four major areas: oncology, digestion, neuroscience and rare diseases, and is also investing in specific R&D in specific areas such as blood products and vaccines
.
  

  For Takeda, 2021 will usher in an inflection point
.
In the first quarter of 2021, Takeda's revenue reached 7.
44 billion U.
S.
dollars, a year-on-year increase of 3.
8%
.
Takeda plans to reach 47 billion U.
S.
dollars in revenue by 2030
.
In this regard, Takeda will increase R&D investment and promote the transformation of production lines, intending to focus on the development of vaccine production business
.
The CEO of Takeda has said that because the dengue fever and new crown vaccines are about to receive regulatory approvals, the vaccines are expected to become a larger part of its product portfolio
.
Takeda's dengue vaccine was submitted to European regulators in March this year, and it plans to apply for approval in South America and Asian countries this year
.
  

  It is worth noting that after 2000, Takeda increased its global expansion and mergers and successively acquired overseas companies such as Syrrx, Millennium Pharmaceuticals, Nycomed, Shire, etc.
, and entered the global pharmaceutical business after acquiring Shire in 2019.
Take the top 10
.
From the perspective of the industry, Takeda's path of gradually growing from a Japanese localized pharmaceutical company to an international pharmaceutical company has certain reference value for domestic pharmaceutical companies
.